Kala Pharmaceuticals is developing innovative ophthalmic treatments based on the company’s Mucosal Penetrating Product (MPP) platform. Kala’s products have an unprecedented ability to rapidly coat and effectively penetrate mucosal tissues resulting in superior therapeutic efficacy and transformative treatment outcomes for patients.
Kala is advancing a diversified pipeline of transformative, topically applied products for treating severe ophthalmic diseases, including ocular inflammation and wet age-related macular degeneration. »GO
Mucosal Penetrating Products (MPPs): Effective new therapeutics that harness the mucus barrier. »GO
Robert Langer on the advantages of Kala’s technology approach. »GO
